Development and validation of a LC/MS/MS method for quantifying the next generation calcineurin inhibitor, voclosporin, in human whole blood.

[1]  K. Papp,et al.  A randomized, multicenter, double-blind, placebo-controlled phase 2 trial of ISA247 in patients with chronic plaque psoriasis. , 2006, Journal of the American Academy of Dermatology.

[2]  B. Matuszewski.  Standard line slopes as a measure of a relative matrix effect in quantitative HPLC-MS bioanalysis. , 2006, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[3]  A H Thomson,et al.  Cost-Effectiveness of Therapeutic Drug Monitoring: A Systematic Review , 2005, Therapeutic drug monitoring.

[4]  R. Morris,et al.  The novel calcineurin inhibitor ISA247: a more potent immunosuppressant than cyclosporine in vitro , 2004, Transplant international : official journal of the European Society for Organ Transplantation.

[5]  S. Griffey,et al.  Compared with Cyclosporine, ISATX247 Significantly Prolongs Renal-Allograft Survival in a Nonhuman Primate Model , 2004, Transplantation.

[6]  Fabio Garofolo,et al.  Bioanalytical Method Validation , 2004 .

[7]  G. Jhangri,et al.  Amelioration of accelerated collagen induced arthritis by a novel calcineurin inhibitor, ISA(TX)247. , 2002, The Journal of rheumatology.

[8]  S. Wong.  Therapeutic drug monitoring for immunosuppressants. , 2001, Clinica chimica acta; international journal of clinical chemistry.

[9]  N. Kneteman,et al.  ISATX247: a novel calcineurin inhibitor. , 2001, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[10]  D. Holt,et al.  Optimizing the use of cyclosporine in renal transplantation. , 1995, Clinical biochemistry.